Endotracheal enucleation and para ‐toluenesulfonamide injection for adenoid cystic carcinoma in the upper trachea: A novel therapeutic approach
We present a case of tracheal adenoid cystic carcinoma (ACC) treated with endotracheal enucleation followed by three doses of para-toluenesulfonamide (PTS)-lipiodol mixture injection. The treatment resulted in tumor eradication, improved airway patency, and absence of recurrence in 1 year, suggesting PTS as a promising alternative for inoperable ACC. AbstractWe present a case of an adenoid cystic carcinoma (ACC) located in the upper trachea, which resulted in significant airway blockage, that was unsuitable for surgical removal due to concerns about functional impairment. Instead, endotracheal enucleation via rigid bron...
Source: Thoracic Cancer - April 19, 2024 Category: Cancer & Oncology Authors: Hsiao ‐Hung Lu,
Shuenn‐Wen Kuo Tags: CASE REPORT Source Type: research
Circulating SMRP and CA ‐125 before and after pleurectomy decortication for pleural mesothelioma
ConclusionsLongitudinal changes in SMRP levels corresponded with a radiographic presence of disease in a subset of patients. SMRP surveillance could aid in detection of local recurrences, whereas CA-125 could be helpful in recognizing abdominal recurrences. (Source: Thoracic Cancer)
Source: Thoracic Cancer - April 17, 2024 Category: Cancer & Oncology Authors: Juuso Paajanen,
Ahmed Sadek,
William G. Richards,
Yue Xie,
Emanuele Mazzola,
Kristina Sidopoulos,
John Kuckelman,
Ritu R. Gill,
Raphael Bueno Tags: ORIGINAL ARTICLE Source Type: research
Efficacy and safety of novel immune checkpoint inhibitor ‐based combinations versus chemotherapy as first‐line treatment for patients with extensive‐stage small cell lung cancer: A network meta‐analysis
ConclusionPD-1/PD-L1 inhibitors-based combinations are associated with significant improvement in both PFS and OS for treatment-na ïve ES-SCLC patients. Benmelstobart plus anlotinib with chemotherapy (CT) yielded better survival benefit versus CT alone or other ICIs + CT with caution for more adverse effects along with the addition of an antiangiogenic agent. (Source: Thoracic Cancer)
Source: Thoracic Cancer - April 16, 2024 Category: Cancer & Oncology Authors: Chuang Yang,
Tiantian Xuan,
Qing Gong,
Xin Dai,
Chengjun Wang,
Rongyu Zhang,
Wen Zhao,
Jian Wang,
Weiming Yue,
Jisheng Li Tags: ORIGINAL ARTICLE Source Type: research
Investigating the predictive factors of thoracic aortic invasion and surgical outcomes in patients with primary lung cancer: A retrospective study
ConclusionIf the chest CT of a patient demonstrates aortic depression due to tumor or loss of fatty tissue between tumor and mediastinum, aortic complications should be considered when planning surgery. (Source: Thoracic Cancer)
Source: Thoracic Cancer - April 16, 2024 Category: Cancer & Oncology Authors: Hideomi Ichinokawa,
Kazuya Takamochi,
Mariko Fukui,
Aritoshi Hattori,
Takeshi Matsunaga,
Kenji Suzuki Tags: ORIGINAL ARTICLE Source Type: research
Continuous immunotherapy beyond progression in clinical practice for small cell lung cancer
We describe the effectiveness of continuous ICIs beyond progression in SCLC. Medical courses of SCLC patients treated with chemo-immunotherapy were retrospectively reviewed at our hospital. The study included 36 patients with a median age of 73 years (range 46–83 years) who introduced chemo-immunotherapy between September 2019 and December 2022. Atezolizumab and durvalumab in combination with platinum plus etoposide were administered in 24 and 12 patients, respectively. The overall response rate was 67% and the disease control rate was 86%. The median progression-free survival and time to treatment failure (TTF) wer...
Source: Thoracic Cancer - April 16, 2024 Category: Cancer & Oncology Authors: Ken Yamamoto,
Taira Ninomaru,
Hideaki Okada,
Katsuya Hirano,
Temiko Shimada,
Akito Hata Tags: BRIEF REPORT Source Type: research
Impact of concurrent medications on the outcome of immunotherapy in non ‐small cell lung carcinoma
ConclusionsThe unnecessary use of NSAIDs along with immunotherapy should be discouraged. (Source: Thoracic Cancer)
Source: Thoracic Cancer - April 16, 2024 Category: Cancer & Oncology Authors: Jun Yamada,
Takafumi Fukui,
Atsuhiko Yatani,
Chihiro Mimura,
Kiyoko Fukuda,
Daisuke Hazama,
Naoko Katsurada,
Tatsuya Nagano,
Masatsugu Yamamoto,
Motoko Tachihara Tags: ORIGINAL ARTICLE Source Type: research
Issue Information
(Source: Thoracic Cancer)
Source: Thoracic Cancer - April 15, 2024 Category: Cancer & Oncology Tags: ISSUE INFORMATION Source Type: research
Surgical outcomes for non ‐small cell lung cancer in younger adults: A population‐based study
ConclusionsOverall, younger patients with NSCLC treated surgically exhibit superior OS and LCSS compared to their older counterparts, although no statistically significant difference in LCSS for stages III –IV was observed between the two age groups. (Source: Thoracic Cancer)
Source: Thoracic Cancer - April 13, 2024 Category: Cancer & Oncology Authors: Zhirong Zhang,
Huandong Huo,
Feng Li,
Jinbai Miao,
Bin Hu,
Shuo Chen Tags: ORIGINAL ARTICLE Source Type: research
Real ‐world evidence of efficacy of pembrolizumab plus chemotherapy and nivolumab plus ipilimumab plus chemotherapy as initial treatment for advanced non‐small cell lung cancer
ConclusionsIn real-world practice, CP demonstrated superior PFS compared with CNI. These findings can inform treatment selection in advanced NSCLC. (Source: Thoracic Cancer)
Source: Thoracic Cancer - April 12, 2024 Category: Cancer & Oncology Authors: Ayami Kaneko,
Nobuaki Kobayashi,
Kenji Miura,
Hiromi Matsumoto,
Kohei Somekawa,
Tomofumi Hirose,
Yukihito Kajita,
Anna Tanaka,
Shuhei Teranishi,
Yu Sairenji,
Hidetoshi Kawashima,
Kentaro Yumoto,
Toshinori Tsukahara,
Nobuhiko Fukuda,
Ryuichi Tags: ORIGINAL ARTICLE Source Type: research
Thoracic skeletal muscle mass predicts mortality in patients with surgery for pleural empyema: A case control study
ConclusionsTSMI was a significant prognostic risk factor for postoperative mortality in patients with pleural empyema. TSMI may be suitable for risk stratification in this disease with high morbidity and mortality, which may have further implications for the selection of the best treatment strategy. (Source: Thoracic Cancer)
Source: Thoracic Cancer - April 11, 2024 Category: Cancer & Oncology Authors: Christian Galata,
Philipp Schiller,
Lukas M üller,
Ioannis Karampinis,
Davor Stamenovic,
Roland Buhl,
Michael Kreuter,
Eric Dominic Roessner Tags: ORIGINAL ARTICLE Source Type: research
Single ‐cell RNA sequencing reveals aberrant sphingolipid metabolism in non‐small cell lung cancer impacts tumor‐associated macrophages and stimulates angiogenesis via macrophage inhibitory factor signaling
ConclusionBased on multiple scRNA-seq datasets, we propose that a MIF-targeted strategy could potentially impede the polarization from M1 to M2 and impair tumor angiogenesis in low-SLM non-small cell lung cancer (NSCLC), demonstrating its potent antitumor efficacy. (Source: Thoracic Cancer)
Source: Thoracic Cancer - April 9, 2024 Category: Cancer & Oncology Authors: Luyan Shen,
Jingtao Liu,
Fengling Hu,
Yifan Fang,
Yaya Wu,
Wei Zhao,
Shaohua Ma Tags: ORIGINAL ARTICLE Source Type: research
Immune cell ‐related prognostic risk model and tumor immune environment modulation in esophageal carcinoma based on single‐cell and bulk RNA sequencing
ConclusionIn summary, our study harnessed multiomics data to delineate the immune profile of esophageal carcinoma patients, provide a method for leveraging molecular signatures of immune cells to identify potential biomarkers, while concurrently providing evidence for the potential benefits of immunotherapy. (Source: Thoracic Cancer)
Source: Thoracic Cancer - April 8, 2024 Category: Cancer & Oncology Authors: Xiao Wen,
Liu Pu,
Zhang Wencheng,
Ma Tengfei,
Wang Guangshun Tags: ORIGINAL ARTICLE Source Type: research
Correction to “Curcumin induces ferroptosis in non‐small‐cell lung cancer via activating autophagy”
(Source: Thoracic Cancer)
Source: Thoracic Cancer - April 6, 2024 Category: Cancer & Oncology Tags: CORRECTION Source Type: research
Issue Information
(Source: Thoracic Cancer)
Source: Thoracic Cancer - April 5, 2024 Category: Cancer & Oncology Tags: ISSUE INFORMATION Source Type: research
Quantitative evaluation of the impact of relaxing eligibility criteria on the risk –benefit profile of drugs for lung cancer based on real‐world data
This study presents a protocol to quantitatively evaluate the impact of relaxing eligibility criteria in common non-small cell lung cancer (NSCLC) protocols in China, on the risk –benefit profile. This involves a detailed explanation of the rationale, framework, and design of REC.MethodsTo evaluate our REC in NSCLC drug trials, we will first construct a structured, cross-dimensional real-world NSCLC database using deep learning methods. We will then establish randomized virtual cohorts and perform benefit –risk assessment using Monte Carlo simulation and propensity matching. Shapley value will be utilized to quantitati...
Source: Thoracic Cancer - April 5, 2024 Category: Cancer & Oncology Authors: Huiyao Huang,
Shuopeng Jia,
Xin Wang,
Huilei Miao,
Hong Fang,
Hanqing He,
Dawei Wu,
Yu Tang,
Ning Li Tags: STUDY PROTOCOL Source Type: research
